AstraZeneca PLC
AZNHealthcareNASDAQDrug Manufacturers - General
Scan Results
Daily timeframeAstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. With a market capitalization of $248.21B, it sits in mega-cap territory. The company offers Imjudo, Datroway, Iressa, Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Crestor, Andexxa, Onglyza, Symlin, XIGDUO XR, Atacand, Atacand HCT, Atacand Plus, Farxiga/Forxiga, Plendil, Modip, Splendil, Munobal, Flodil, Tenormin, Tenormine, Prenormine, Atenol, Zestril, Brilinta/Brilique, Komboglyze, Qtern, Wainua, Byetta, Lokelma, Seloken ZOK, Toprol-XL, Betaloc ZOK, XIGDUO, Accolate, Accoleit, Vanticon, Bricanyl Respules, Eklira Genuair/Tudorza/Bretaris, Pulmicort Turbuhaler, Symbicort Turbuhaler, Airsupra, Bricanyl Turbuhaler, Fasenra, Rhinocort, Tezspire, Bevespi Aerosphere, Daliresp/Daxas, Oxis Turbuhaler, Saphnelo, Breztri Aerosphere, Duaklir Genuair, Pulmicort Respules, and Symbicort pMDI.
Market Cap
$248.21B
Beta
0.20
P/E (TTM)
23.92
P/E (Fwd)
14.09
EPS (TTM)
$6.69
EPS (Fwd)
$11.36
ROE
22.0%
ROA
8.0%
Cash
$4.97B
Total Debt
$32.35B
Free CF
$4.91B
52W Change
0.7%
Annual Financials
Cash vs Debt
Where AZN stands vs its 150-day and 200-day moving averages
As of the August 25, 2026 close, AZN finished 9.79% below its 150-day moving average ($184.81) and 9.22% below its 200-day moving average ($183.64). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is AZN overbought or oversold?
At the August 25, 2026 close, AZN's RSI(14) was 73.3, in overbought territory (above 70). The MACD histogram was positive, so short-term momentum leaned bullish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
AstraZeneca PLC carries $32.35B in total debt against $4.97B in cash reserves — debt is roughly 6.5x the cash position. Managing this leverage effectively will be important for long-term financial stability. The company generates $4.91B in free cash flow annually, which funds everything from R&D to shareholder returns without needing external financing. Return on equity stands at 22.0%, which is strong for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. An ROA of 8.0% suggests reasonable efficiency in deploying the company's asset base. Revenue has grown from $44.35B (2022) to $58.74B (2025), reflecting a 32% increase over the period.
The relatively low beta of 0.20 suggests AZN is a less volatile holding compared to the broader index. AstraZeneca PLC carries a heavier debt load relative to its cash position, which introduces financial risk that investors should weigh. These risk factors are not exhaustive — macroeconomic shifts, regulatory changes, and competitive dynamics can all influence AstraZeneca PLC's trajectory.